AbbVie, Voyager sign $1.2bn agreement for anti-tau antibodies aimed at CNS diseases; deal later terminated
Executive Summary
AbbVie Inc. and Voyager Therapeutics Inc. are teaming up in the development of vectorized tau antibodies for treating neurodegenerative conditions including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice